RT Journal Article
SR Electronic
T1 Uptake of SARS-CoV-2 workplace testing programs, March 2020 to March 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.29.21259730
DO 10.1101/2021.06.29.21259730
A1 Duarte, Nathan
A1 D’Mello, Sean
A1 Duarte, Natalie A
A1 Rocco, Simona
A1 Van Wyk, Jordan
A1 Pillai, Abhinav Arun
A1 Liu, Michael
A1 Williamson, Tyler
A1 Arora, Rahul K
YR 2021
UL http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259730.abstract
AB Objective To track uptake of workplace SARS-CoV-2 testing programs using publicly-available data (e.g., press releases), supplementing findings from employer surveys.Methods We tracked testing programs reported by 1,159 Canadian and 1,081 international employers across sectors from March 1, 2020 to March 31, 2021. We analyzed trends in uptake of testing programs, including over time and by workplace setting.Results 9.5% (n=110) of Canadian employers and 24.6% (n=266) of international employers tracked reported testing. The prevalence of reported testing programs was less than 20% in some settings associated with high risk of transmission including retail and customer-facing environments, and indoor and mixed blue collar workplaces.Conclusions Publicly-available data suggest that fewer employers are testing than indicated by surveys. Workplace safety in high-risk workplaces could be further improved by implementing testing strategies that deploy both screening and diagnostic tests.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Public Health Agency of Canada through Canada's COVID-19 Immunity Task Force.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:REB approval and waiver was not necessary as this was a secondary analysis of publicly-available data; no patient or individual-level data was involved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, ND, upon reasonable request.